Cline Scientific
Annual Report for Cline Scientific AB (publ), 556867-8238, for the period 1 January - 31 December 2022
The report is published at www.clinescientific.com/financial-reports
The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 8:30 CET on 29 March 2023.
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.
Cline Scientific AB (publ) Phone: 031-387 55 55
Argongatan 2C Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
| Datum | 2023-03-29, kl 08:30 |
| Källa | Cision |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.